The second largest UK drugmaker, who have some involvement with diabetes, will cut a further 6,000 jobs over the next four year period. The news comes in addition to the 7,600 redundancies already announced by AstraZeneca . By 2013, over 13,000 jobs will have gone at the company.
Despite healthy pre-tax profits, chief executive David Brennan was reported as commenting: "The exact outcome is dependent, in part, on the extent of the impact of global economic conditions experienced over the course of the year."
Although AstraZeneca do have involvement in the diabetes industry, their blockbuster drugs are Nexium, and ulcer treatment and Crestor, a cholesterol drug. AstraZeneca face 9,000 lawsuits alleging that depression drug Seroquel can cause diabetes and other health problems.
Pharmaceutical company will shed thousands of jobs
Mon, 02 Feb 2009
Recommended links
Diabetes newsletterDiabetes based financial services
Diabetes forum
Diabetes chat
Major diabetes risk amongst maoris
Laughter good for diabetes
Diabetes company foresee device growth
Company files for diabetes drug application
Company sets up diabetes research fund
Company sponsors diabetes day
Diabetes drug company say efficiency is proven
Diabetes company get Canadian approval
Diabetes drug company trial hitch
Pfizer in major bid for drug company
Diabetes Company says new drug is efficient
Diabetes company shares hit a low
Diabetes test patent given to company
Diabetes drug company shares climb
New company in type 2 diabetes development
Diabetes company faces further controversy
Diabetes drug company sales fall
Company gets boost in diabetes battle
Diabetes Drug Company losing less
Diabetes company looking for drug approval
Diabetes drug company call for approval
Drug company will continue diabetes trial
Diabetes company sees potential in Russia
Diabetes company profits continue to climb





Join us